BRIDGEWATER, N.J., Feb. 23, 2012 /PRNewswire/ -- Sanofi US
announced today that it is accepting entries for the Data Design
Diabetes™ Innovation Challenge. The Innovation Challenge is aligned
with the United States
government's initiative to use an open dialogue to drive action
toward a three-part aim: innovation in the quality, delivery and
cost of diabetes care. The kickoff earlier this year crowd-sourced
answers to the question, "What matters most to you?" as it relates
to diabetes, and prizes include more than $200,000 in awards, industry-leading mentorship
and real-world community response. Innovators are encouraged to
submit concepts to www.DataDesignDiabetes.com through March 23, 2012.
(Logo: http://photos.prnewswire.com/prnh/20110624/NY25833LOGO
)
"Sanofi strives to be a valued partner to the diabetes community
offering innovative, integrated and
personalized solutions that address the real needs people have
in managing their diabetes every day," said Dennis Urbaniak, Vice President, Head of U.S.
Diabetes, Sanofi US. "The Innovation Challenge offers us an
opportunity to foster innovation solutions for the nearly 26
million people living with diabetes today."
2012 Data Design Diabetes™ Innovation Challenge parameters
include:
- Improve the outcomes and/or experience of caregivers,
family/friends, healthcare providers and/or people living with
diabetes in the US.
- Advance the quality, effectiveness and delivery of diabetes
care in the US.
- Enable people within the diabetes ecosystem to feel in
control.
- Reduce the cost of care without compromising the quality and
delivery of care.
- Create a concept that scales and can be accelerated and
distributed with ease.
- Reflect human-centered design.
- Demonstrate the ability to develop the concept into an
illustrative prototype in one month.
Industry leaders will mentor five semi-finalists, selected by a
panel of judges, and all intellectual property and equity will
remain the property of its creators. Last year's winner, Ginger.io,
uses an app to alert caregivers to concerning behavioral changes.
Following the Innovation Challenge, Ginger.io raised $1.7MM in seed funding and expanded its company,
which now includes 7 full-time employees. "The first Innovation
Challenge allowed us to expand our ideas to help people with
diabetes in a new way," said Ginger.io co-founders, Karan Singh and Anmol
Madan. "We encourage anyone with an innovative idea who
wants to make a difference to submit an entry."
The 2012 Data Design Diabetes™ Innovation Challenge prizes
include:
- Access to entrepreneurial resources, through a partnership with
Startup America.
- A Design & Prototyping Bootcamp to orient the
semi-finalists to human-centered design and user experience,
develop the understanding of diabetes and teach rapid prototyping
methodologies.
- Total monetary awards of more than $200,000 by Sanofi US, along with invaluable
mentorship and ongoing support.
For a complete list of the Innovation Challenge rules and to
submit a concept, visit http://www.DataDesignDiabetes.com. To
follow the Innovation Challenge as it progresses, visit Twitter,
Facebook, or the Data Design Diabetes blog.
About the Data Design Diabetes™ Innovation Challenge
Data Design Diabetes™ is a next-generation challenge offered by
Sanofi US that brings together the richness of open datasets, the
values of human-centered design, and the leading-edge methodology
of the top innovation accelerators to find the next breakthrough to
help millions of Americans living with diabetes.
About the Sanofi Diabetes Division
Sanofi strives to help people manage the complex challenges of
diabetes by delivering innovative, integrated and personalized
solutions. Driven by valuable insight that comes from listening to
and engaging with people living with diabetes, the Company is
forming partnerships to offer diagnostics, therapies, services, and
devices. Sanofi markets both injectable and oral medications for
people with type 1 or type 2 diabetes. Investigational compounds in
the pipeline include an injectable GLP-1 agonist being studied as a
single agent, in combination with basal insulins, and/or in
combination with oral antidiabetic agents.
About Sanofi
Sanofi, a global and diversified healthcare leader, discovers,
develops and distributes therapeutic solutions focused on patients'
needs. Sanofi has core strengths in the field of healthcare with
seven growth platforms: diabetes solutions, human vaccines,
innovative drugs, rare diseases, consumer healthcare, emerging
markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi is the holding company of a consolidated group of
subsidiaries and operates in the United
States as Sanofi US, also referred to as Sanofi-aventis U.S.
LLC. For more information on Sanofi US, please visit
http://www.sanofi.us or call 1-800-981-2491.
Contact:
Media
Relations
Lindsey Schedler
Tel.: 908 981 6754
Lindsey.Schedler@Sanofi.com
US.GLA.12.01.134
SOURCE Sanofi
